KEYNOTE‐033: randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD‐L1‐positive, advanced NSCLC

S Ren, J Feng, S Ma, HJ Chen, Z Ma… - … Journal of Cancer, 2023 - Wiley Online Library
Abstract KEYNOTE‐033 (NCT02864394) was a multicountry, open‐label, phase 3 study that
compared pembrolizumab vs docetaxel in previously treated, programmed death‐ligand 1 …
被引用次数：9 相关文章

KEYNOTE-033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD-L1-positive, advanced NSCLC.

S Ren, J Feng, S Ma, H Chen, Z Ma… - … Journal of Cancer, 2023 - europepmc.org
KEYNOTE-033 (NCT02864394) was a multicountry, open-label, phase 3 study that
compared pembrolizumab vs docetaxel in previously treated, programmed death-ligand 1 …

KEYNOTE-033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD-L1-positive, advanced NSCLC

S Ren, J Feng, S Ma, HJ Chen, Z Ma… - … Journal of Cancer, 2023 - mahidol.elsevierpure.com
Abstract KEYNOTE-033 (NCT02864394) was a multicountry, open-label, phase 3 study that
compared pembrolizumab vs docetaxel in previously treated, programmed death-ligand 1 …

KEYNOTE-033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD-L1-positive, advanced NSCLC

S Ren, J Feng, S Ma, HJ Chen, Z Ma… - … journal of cancer, 2023 - pubmed.ncbi.nlm.nih.gov
KEYNOTE-033 (NCT02864394) was a multicountry, open-label, phase 3 study that
compared pembrolizumab vs docetaxel in previously treated, programmed death-ligand 1 …

KEYNOTE-033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD-L1-positive, advanced NSCLC

S Ren, J Feng, S Ma, H Chen, Z Ma, C Huang, L Zhang… - 2023 - essuir.sumdu.edu.ua
KEYNOTE-033 (NCT02864394) was a multicountry, open-label, phase 3 study that
compared pembrolizumab vs docetaxel in previously treated, programmed death-ligand 1 …
[PDF] sumdu.edu.ua

[PDF][PDF] KEYNOTE-033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD-L1-positive, advanced NSCLC

S Ren, J Feng, S Ma, HJ Chen, Z Ma, C Huang… - 2023 - essuir.sumdu.edu.ua
Abstract KEYNOTE-033 (NCT02864394) was a multicountry, open-label, phase 3 study that
compared pembrolizumab vs docetaxel in previously treated, programmed deathligand 1 …